Phase I study of CPT-11 and bolus 5-FU/<Emphasis Type="Italic">l</Emphasis>-leucovorin in patients with metastatic colorectal cancer |
| |
Authors: | Hiromitsu?Fujishima Ikuo?Kikuchi Osamu?Miyanaga Akira?Ueda Eishi?Baba Kenji?Mitsugi Mine?Harada Email author" target="_blank">Shuji?NakanoEmail author |
| |
Institution: | (1) Department of Internal Medicine, Miyazaki Prefectural Hospital, Miyazaki, Japan;(2) First Department of Internal Medicine, Graduate School of Medicine, Kyushu University, Fukuoka, Japan;(3) Department of Biosystemic Science of Medicine, Graduate School of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan |
| |
Abstract: | Background Irinotecan (CPT-11) and bolus 5-fluorouracil (5-FU)/leucovorin (LV) administered weekly for 4 weeks every 42 days (Saltz regimen) is active but substantially toxic in patients with metastatic colorectal cancer (CRC). The efficacy and toxicity of this regimen, however, have not been determined in Japanese patients with metastatic CRC.Methods We investigated the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) for CPT-11 given i.v. (90-min infusion) and bolus 5-FU plus biologically active l-LV administered weekly for 3 weeks every 28 days (modified Saltz regimen) in Japanese patients with metastatic CRC. Eighteen patients with measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, and adequate organ functions were enrolled.Results At dose level 2 (CPT-11, 100mg/m2; 5-FU, 400mg/m2; and l-LV, 25mg/body), 1 of 6 patients had DLT (febrile neutropenia). At dose level 3 (CPT-11, 100mg/m2; 5-FU, 500mg/m2; and l-LV, 25mg/body), 2 of 6 patients had DLT (febrile neutropenia and grade 4 neutropenia lasting more than 4 days). To determine whether level 3 was the MTD level, an additional 3 patients were treated at this level, but no DLT was observed. Consequently, 2 of 9 patients had DLT at level 3, this level thus being considered as the RD. At this level, grade 3–4 neutropenia was common but manageable. Nonhematological toxicities were mild. Seven partial responses were observed in the 18 enrolled patients (response rate RR], 39%), and 8 patients (44%) experienced stable disease.Conclusion This CPT-11/5-FU/l-LV regimen administered weekly for 3 weeks every 28 days has substantial antitumor activity, with manageable toxicities. A multicenter phase II study is currently underway. |
| |
Keywords: | 5-Fluorouracil Irinotecan l-Leucovorin Phase I Colorectal cancer |
本文献已被 PubMed SpringerLink 等数据库收录! |
|